Treatment Duration and Clinical Management in Newly Diagnosed Multiple Myeloma

Dr. Ajai Chari and NP Samantha Shenoy discuss practical considerations for long-term management of newly diagnosed multiple myeloma (NDMM), focusing on treatment duration, ongoing therapy, and patient-centered care. The faculty explore the rationale for continuous treatment approaches and how response depth, including minimal residual disease (MRD) negativity, may continue to evolve with extended therapy. The conversation emphasizes that treatment duration decisions should be individualized based on tolerability, patient preferences, comorbidities, and long-term management goals. Dr. Chari and NP Shenoy also review real-world follow-up strategies, highlighting the importance of multidisciplinary collaboration, symptom management, patient education, and shared decision-making throughout the treatment journey. Practical insights are provided regarding the role of advanced practice providers in supporting adherence, monitoring treatment-related toxicities, and helping patients navigate prolonged therapy while maintaining quality of life and optimizing clinical outcomes in NDMM.